This inventor holds 2 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Daiichi Sankyo Company, Limited, National Institutes of Biomedical Innovation, Health and Nutrition. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2019-2021
Title: Fumihiko Takeshita: Innovator in Immunology
Introduction
Fumihiko Takeshita is an accomplished inventor based in Tokyo, Japan. He has made significant contributions to the field of immunology, as evidenced by his two patents that focus on novel oligonucleotide complexes with immunopotentiating activity.
Latest Patents
Fumihiko Takeshita’s latest patents include innovative formulations featuring an oligodeoxynucleotide that contains a humanized K type CpG oligodeoxynucleotide paired with poly deoxyadenylate. This complex is specifically designed with the poly deoxyadenylate placed on the 3'-side of the humanized K type CpG oligodeoxynucleotide. Additionally, his inventions encompass a sophisticated complex that includes the aforementioned oligodeoxynucleotide and β-1,3-glucan, further enhancing its potential applications.
Career Highlights
Throughout his career, Fumihiko Takeshita has worked at esteemed organizations such as the National Institutes of Biomedical Innovation, Health and Nutrition and Daiichi Sankyo Company, Limited. His work within these institutions has helped to advance research in biomedicine and related fields.
Collaborations
Fumihiko Takeshita has collaborated with notable colleagues, including Ken Ishii and Kouji Kobiyama. These partnerships underscore the collaborative spirit often found in the innovative landscape of biomedical research.
Conclusion
In summary, Fumihiko Takeshita stands out as a prominent inventor in the realm of immunology, with a focus on developing advanced oligonucleotide complexes. His ongoing contributions continue to impact the landscape of biomedical innovation positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile